NCT03595917 - ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 24, 2018

Primary Completion Date

November 1, 2025

Study Completion Date

November 1, 2026

Conditions

B-cell Acute Lymphoblastic LeukemiaChronic Myeloid Leukemia (CML) in Lymphoid Blast CrisisPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL

Interventions

DRUG

ABL001

•ABL001 is administered daily per 28 day cycle

DRUG

Dasatinib

Fixed doses oral once a day per 28 day cycle

DRUG

Prednisone

Fixed doses oral once a day per 28 day cycle Prednisone will be tapered and stop during cycle 2.

DRUG

Blinatumomab

By intravenous continuous infusion beginning no earlier than cycle 2 day 1 of protocol therapy Day 1-28 of each 42-day cycle, cycles 2-6, total of 5 cycles

Trial Locations (4)

14203

RECRUITING

Roswell Park Comprehensive Cancer Center, Buffalo

60637

RECRUITING

University of Chicago Comprehensive Cancer Center, Chicago

02115

RECRUITING

Dana Farber Cancer Institute, Boston

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston